Clinical trial
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
NCT03288974 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 28, 2017
- Completion date
- November 16, 2023
- Enrollment
- 397 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.